We have investigated the possible antidiabetic properties of fruit extracts of Emblica officinalis Gaertn., Terminalia chebula Retz. and T. bellirica Roxb., individually and in combination (Triphala) in a high fructose diet induced rat model of insulin resistance. In the first part of the study, normal animals were studied for hypoglycemic activity. In the second part, animals were given a high fructose diet (HFD) for 40 days, for the last 20 days of which fruit extracts were also given. Body weight, fasting plasma glucose (FPG), and area under the curve (AUC) of the oral glucose tolerance test (OGTT) were assessed at the baseline, and at days 20 and 40. Fasting plasma insulin levels and the homeostasis model assessment (HOMA) resistance index were also assessed at baseline, 20 and 40 days. Fasting lipid levels were measured at the end of the study. During the first part of the investigation, in which extracts were given to normal animals, T. chebula showed significant hypoglycemic activity. During the second part of the study, in which the extracts were given to HFD fed rats, T. chebula caused a significant decrease in FPG and AUC. Emblica officinalis and Triphala caused a normalization of FPG. T. bellirica caused a reduction in AUC levels, but had no effect on FPG levels. T. bellirica caused a reduction in serum total cholesterol, triglyceride and low density lipoprotein levels. In conclusion, all three components of Triphala showed significant antidiabetic properties. T. bellirica, in addition, showed hypolipidemic activity.
Type-2 diabetes mellitus (DM) is a metabolic disorder that is associated with three basic pathophysiological abnormalities: impaired insulin secretion, excessive hepatic glucose production, and insulin resistance in skeletal muscle, liver, and adipose tissue [1] . Since the completion of the Diabetes Control and Complications Trial (DCCT) [2] and the UK Prospective Diabetes Study (UKPDS) [3] , it is now clear that aggressive control of hyperglycemia in patients with diabetes can either prevent or delay the onset of complications, such as retinopathy, nephropathy and neuropathy.
The pharmacological agents available for the treatment of type-2 diabetes either suppress glucose production or augment glucose utilization. However, neither mono nor combination therapy of these agents is completely successful in ameliorating type 2 diabetes for many patients. These therapies have limited efficacy, limited tolerability and significant mechanism-based side effects [4] . Thus, more efficacious agents are desperately needed [5] .
Triphala is among the most common formulas used in Traditional Ayurvedic Medicine (TAM). Triphala is comprised of the fruits of Emblica officinalis Gaertn. (Euphorbiaceae) or Amla, Terminalia bellirica Roxb. or Baheda, and Terminalia chebula Retz.(Combretaceae) or Harad, also known as the three myrobalans. Triphala (T) is mentioned throughout the ancient literature of Ayurvedic medicine as a tonic, alterative and gentle aperient (laxative). It is highly prized for its ability to regulate the processes of digestion and elimination [6] .
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Triphala is employed in the treatment of headache, dyspepsia, constipation, liver conditions, ascites, and leucorrhoea. Triphala is reported to possess adaptogenic, radioprotective, antimicrobial, antioxidant and antimutagenic properties. [7] .
The active principles of Triphala are predominantly hydrolysable tannins. T. bellirica fruit contains about 20 to 30% of tannins, mostly consisting of gallic acid, ellagic acid, ethyl gallate, galloyl glucose and chebulaginic acid. The fruit also contains phyllemblin and other sugars. E. officinalis (Amla; EO) is widely distributed throughout the tropics and sub-tropics. The fruit is a rich source of vitamin C and also contains pectin, glucose, tannins and phyllemblin. T. chebula (TC, myrobalans) fruits are also an important source of tannin. The tannins of myrobalans are of the pyrogallol type, which on hydrolysis yield chebulic acid and D-galloyl glucose [8] . Studies by Sabu and Kuttan [9] have shown that the individual components of Triphala inhibit lipid peroxide formation and could scavenge hydroxyl and superoxide radicals. Recently, studies have pointed out that their antioxidant activity correlates with their antidiabetic property and that they are also helpful in decreasing the complications of DM [10, 11] . Tannins are effective antioxidants and are active constituents of several natural extracts, and it is possible that they contribute to the medicinal properties of several herbal preparations. Several studies recently have shown hypoglycemic activity of T. chebula [12] .
High fructose intake leads to a reduced glucose disposal rate and reduced suppressibility of hepatic glucose production at an insulin concentration in the mid-physiological range. Both high fructose and high fat diets produce a state of insulin resistance, but do not cause overt diabetes. This animal model may resemble certain features of the non-diabetic human insulin resistant states of obesity and impaired glucose tolerance [13] . In this present study we have investigated the possible antidiabetic properties of fruit extracts of E. officinalis, T. chebula and T. bellirica, individually and in combination (Triphala) in a high fructose diet (HFD) induced rat model of insulin resistance.
Hypoglycemic activity in normal rats: Figure 1 shows the sequential plasma glucose levels up to four hours after drug administration to normal rats. In the three groups treated with E. officinalis, T. bellirica and Triphala, respectively, the fall in plasma glucose was similar to that of the vehicle. At no time was the plasma glucose level statistically different from that of the vehicle treated group. However, treatment with glipizide caused a significant fall in plasma glucose levels, starting from one hour after administration of the drug. Administration of T. chebula at a dose of 100 mg/kg showed a significant decrease in plasma glucose levels, which decreased from a baseline value of 78.5±10.4 mg/dL to 55.0±12.4 mg/dL in 4 hours. This effect started one hour after administration and continued for the total observation period of four hours. The maximum fall in plasma glucose levels (26.2±5.6 mg/dL) was seen at two hours post administration. At four hours the plasma glucose in the T. chebula treated groups was significantly lower than that of the glipizide treated group.
Antidiabetic activity in rats with high fructose (HFD) diet. Table 1 shows that there were no differences in the baseline parameters (day 1) of the animals studied. However, at the end of 40 days, there was a significant increase in the weight of the animals in the HFD treated group compared to the vehicle group. Treatment with either Triphala or T. bellirica was associated with a weight gain that was similar to the vehicle treated group, in spite of HFD feeding ( Figure 2 ). However, treatment with either E. officinalis or T. chebula caused no significant change in weight gain due to HFD feeding. HFD administration resulted in a significant increase in FPG at 20 and 40 days. Both glipizide and pioglitazone caused a significant reduction in FPG. Among the three herbal extracts, T. chebula had a significant hypoglycemic effect. At the end of 40 days the FPG was even lower than that of the vehicle control group. E. officinalis and Triphala also caused a reduction in FPG and after 40 days, the FPG was similar to that of the vehicle treated group. T. bellirica had no effect on FPG levels after 40 days ( Figure 3 ). HFD feeding caused a significant increase in AUC (area under the oral glucose tolerance curve) from the baseline at both 20 and 40 days, which was significantly higher than that of the normal animals.
Glipizide caused a significant decrease in AUC at 40 days. However, pioglitazine did not significantly decrease AUC. T. chebula and Triphala also caused a significant reduction in AUC, similar to that of the glipizide treated groups. T. bellirica caused a reduction in AUC similar to that of the normal animals. E. officinalis had no effect on AUC levels ( Figure 4 ). Fasting plasma insulin (FPI) levels were measured 20 and 40 days after treatment with HFD. HFD feeding caused a significant increase in FPI levels, as did treatment with glipizide, while treatment with pioglitazone caused a significant decrease in FPI levels. T. chebula caused a significant increase in FPI levels comparable to that of the glipizide treated groups ( Figure 5 ). The HOMA (homeostasis model assessment) resistance index was measured 20 and 40 days after treatment with HFD. HFD caused a significant increase in the HOMA index at 40 days, as compared to that at 20 days, but pioglitazone caused a significant decrease in HOMA index at 40 days. Post hoc comparisons showed that glipizide treatment did not decrease the HOMA index to normal levels, when compared to the normal vehicle treated group. Also, T. chebula and Triphala decreased HOMA levels, which were similar to those of the normal vehicle group, but E. officinalis and T. bellirica had no effect on HOMA levels ( Figure 6 ).
Ethnopharmacology and natural product drug discovery remain a significant hope in the current target-rich, lead-poor scenario. Many modern drugs have their origin in traditional medicine and ethnopharmacology. Detailed pharmacological characterization of the herbal medicines needs an insight into the mode of action. Considering the mode of action of the currently available agents, we applied a logical approach. Broadly, available agents either stimulate insulin secretion or have an insulin sensitizing action. If any drug has insulin secreting action, it would decrease the plasma glucose level irrespective of its baseline value.
It was the aim of our first set of experiments to explore the hypoglycemic activity of individual components of Triphala alone and in combination (Triphala) in normal rats. T. chebula caused a significant reduction in FPG levels during the four hour observation period, thus demonstrating a novel hypoglycemic activity. The other herbal extracts did not have any immediate hypoglycemic activity. In the second part of the study, the herbal extracts were tested for efficacy in HFD feeding induced insulin resistance. HFD caused the development of an insulin resistant state with increased levels of FPG, AUC and FPI, and increased HOMA index.
Long term administration of T. chebula led to a significant decrease in FPG and significant increase in FPI insulin levels, suggesting a novel insulin secretagogue-like action. However, this was associated with a reduction in the HOMA resistance index, suggesting either an additive insulin sensitizing effect or just an improvement in insulin secretion, with reduction in FPG. Thus, in this study we have demonstrated a novel antidiabetic activity of T. chebula in a rat model of insulin resistance. Chronic administration of E. officinalis also led to a small, but significant fall in FPG levels, although acute administration has shown no benefit. No previous study has been reported for E. officinalis in models of insulin resistance. This was associated with a trend towards reduction in AUC and FPI levels, and an increase in weight gain, suggesting a novel insulin sensitizing effect. E. officinalis has not shown any benefit in models of type 1 diabetes, like streptozotocin induced diabetes. Models for type 1 DM may not be discriminative enough for screening of either insulin sensitizers or drugs that cannot increase endogenous insulin secretion.
Chronic administration of T. bellirica had no effect on either FPG or FPI levels. However, there was a small but significant reduction in AUC. Thus, T. bellirica seemed to have an effect on post-prandial blood glucose levels by decreasing intestinal glucose absorption. Unlike the previous two extracts, this was associated with a lesser weight gain in the T. bellirica group. There was also a significant reduction in fasting lipid levels. Chronic administration of Triphala also caused a significant reduction in FPG, AUC and fasting lipid levels. The three components of Triphala may be synergistic in reducing both fasting and post-prandial blood glucose levels. Thus, the three components of Triphala individually have antidiabetic properties. The combination was significantly effective in reducing all the parameters of insulin resistance.
The high fructose feeding induced insulin resistance model is good for screening drugs for antidiabetic activity. All the pathophysiological features of insulin resistance are reproduced in this model. The only limitation is that FPG levels are only mildly elevated, necessitating a prolonged administration. Importantly, unlike models of Type 1 DM, drugs with seemingly different modes of action can be tested in this model, as was seen in our study. Also, some drugs that can be missed in the type 1 model can show efficacy in this one. Cost effectiveness over other models is also an advantage. In the end we conclude that the different components of Triphala show antidiabetic properties in HFD fed insulin resistant rats and further research should be undertaken to elucidate the active principles.
Experimental
Individually caged Wistar rats, 10-14 wks old, were maintained under standard laboratory conditions (12 h light and dark cycle). The rats had free access to food and water and were fed with either a standard rat chow diet or a special high fructose diet, according to the protocol. The Institute animal ethics committee approved the study and all the procedures were carried out according to guidelines in the "Declaration of Helsinki" and the CPCSEA guidelines for animal experimentation in India. 
Preparation of plant extract:
The dried fruits and herbs were powdered, and 50g of each was soaked overnight in 150 mL of distilled water at room temperature (about 25 o C). Next morning, the extract was filtered, first through cheese cloth and then through cotton. The filtrate was centrifuged at 1000 rpm for 10 mins at room temperature and the supernatant then evaporated under reduced pressure in a rotary evaporator to 25 mL. The concentrated extract was used for the experiment.
Evaluation of hypoglycemic activity in normal rats:
The rats (60) were divided into ten groups. Food was withdrawn and the extracts in doses of 50 and 100 mg/kg body weight were administered by gavage to the appropriate group of rats. One group received vehicle only and another group glipizide (0.9 mg/kg), which were used as controls for comparison. Blood samples were collected at the start, as well as after 30 mins, 1, 2, and 4 h for measurement of blood glucose levels. Further studies used the highest dose of each extract.
Effect on HFD induced insulin resistance: Fortyeight rats were taken and divided into groups, each containing six animals. Seven groups were fed with HFD for 40 days and one group was fed normal diet only. Among these, four groups received Triphala and extracts of its individual components in doses of 100 mg/kg body weight, respectively. Other groups received either glipizide (0.9 mg/kg), pioglitazone (2.7 mg/kg) or vehicle. All the animals were weighed at the start, and after 20 and 40 days. The oral glucose tolerance test (OGTT) was carried out at days 0, 20 and 40. Fasting plasma glucose level was measured at the start and at the end of each week. Fasting plasma insulin level was measured after 20 and 40 days. Fasting lipid levels were measured at the end of the study.
Oral glucose tolerance test: From overnight fasted diabetic rats, blood samples were collected and fasting plasma glucose was estimated. Then water (equivalent to the water extract to be given later) was given to the rats. After 90 minutes, fasting blood was collected and the blood glucose value determined. This served as the zero hour value. Then glucose (2 g/kg) was given orally and blood was collected at intervals of 30 min, 1 and 2 h, again for glucose estimation. The area under the oral glucose tolerance curve (AUC) was calculated according to the trapezoidal rule.
Biochemical parameters
Plasma glucose estimation: Blood samples (0.1 mL) for plasma glucose were collected in heparinized tubes from the tail vein of the rats. Sodium fluoride was added to the tubes. For fasting blood glucose, samples were collected after an overnight fast. Glucose level estimation was carried out by the glucose oxidase method described by Trinder [14] . For this purpose, commercial kits were purchased from CDR Diagnostics, Hyderabad, and the manufacturer′s instructions were followed.
Plasma insulin level measurement: Plasma samples for insulin estimation were stored at -20 0 C. Insulin level was measured by rat insulin ELISA, purchased from Mercodia AB, Uppsala, Sweden and following the manufacturer's instructions.
Lipid profile estimation:
Plasma was separated by centrifuging at 3000 rpm. Plasma total cholesterol and triglycerides were measured enzymatically (Randox Laboratories Ltd. UK) on a digital colorimeter (Digichem economy). For HDL cholesterol measurement (AUTOPAK, Bayer Diagnostics India Ltd), the samples were initially treated with phosphotungstic acid and magnesium chloride. The samples were centrifuged and HDL was assayed in the supernatant by the enzymatic cholesterol method, using cholesterol esterase, cholesterol oxidase, peroxidase, and the chromogen, 4-aminoantipyrine/phenol. Final concentrations were determined on a digital colorimeter (Digichem economy). LDL cholesterol was calculated from the Friedwald equation.
Insulin resistance assessment: Insulin resistance was calculated using homeostasis (HOMA), according to Mathews et al. [15] . This model incorporates, in a mathematical expression, measures of both fasting plasma concentrations of glucose and insulin. It calculates the index of insulin resistance from the formula given below.
HOMA resistance index: insulin (μU mL -1 ) × glucose ( mM) 22.5
Blood sample collection: All the blood samples were collected from rat tail vein in heparinised test tubes. For plasma glucose estimation, sodium fluoride was added to the tubes. In the case of plasma insulin estimation, plasma samples, after centrifuging at 3000 rpm for 10 minutes, were stored at -20 0 C.
Statistical analysis:
All the data are expressed as mean±SD. Inter-group comparisons were made using ANOVA, followed by post-hoc Tukey's test. A P value less than 0.05 was considered significant. All the figures represent time dependent changes at days 1, 20 and 40 of high fructose diet feeding and have been analyzed by repeated measures ANOVA.
